Navigation Links
Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial

SCHAUMBURG, Ill., Feb. 9 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections, in a 500mg single-dose vial.

The 500mg single-dose vial expands Sagent's existing line of Cefazolin products beyond the 1g single-dose vials and 10g pharmacy bulk package vials launched in March 2008. All doses are completely latex-free and include enhanced packaging features such as bar-coding and labeling designed to reduce confusion among doses.

"The innovative labeling we brought to our other Cefazolin products is now available on a 500 mg single-use vial, allowing clinicians access to an extended line of Cefazolin for injection designed with medication safety in mind," said Lorin Drake vice president of sales and marketing at Sagent Pharmaceuticals. "Our enhanced Cefazolin packaging designs incorporate specific features in response to needs expressed by our customers. We are proud to provide practical solutions designed to improve the safety and care of patients in the dose sizes most needed."

Sagent will begin marketing and shipping Cefazolin in the 500mg single-dose vials immediately.

About Cefazolin

Cefazolin for injection, USP, is the generic equivalent of KEFZOL(R), an antibiotic used to treat bacterial infections. Cefazolin for injection, USP, is indicated for serious infections such as those of the respiratory, biliary and urinary tracts, skin and skin structure infections, bone and joint infections, and other infections caused by E. coli, S. pneumoniae, S. aureus, and various strains of streptococci. Prophylactic Cefazolin for injection, USP, preoperative, intraopertative and postoperative administration can be effective in reducing the incidence of certain surgical infections. The most common adverse effects may include loss of appetite, nausea, vomiting, diarrhea, or headache, as well as pain or tenderness at the injection site. Less common adverse effects include dark urine, easy bruising/bleeding, irregular heartbeat, seizures, unusual weakness, yellowing eyes or skin, and rarely, pseudomembranous colitis.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP
6. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/24/2015)... FAR HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... University, as the recipient of the 2016 USGA Green Section Award. Presented annually since ... of golf through his or her work with turfgrass. , Clarke, of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
Breaking Biology Technology:
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
(Date:10/22/2015)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... the comparable quarter last year to $470.0 million. Net income for ... per diluted share. --> --> ... grew 39 percent over the prior year period to $56.9 million, ...
Breaking Biology News(10 mins):